Stemline Therapeutics (STML) Given Daily News Sentiment Score of 0.17

News headlines about Stemline Therapeutics (NASDAQ:STML) have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Stemline Therapeutics earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.6715498492624 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

A number of research firms have recently commented on STML. ValuEngine cut Stemline Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. HC Wainwright set a $34.00 target price on Stemline Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 9th. Finally, Cowen restated a “buy” rating on shares of Stemline Therapeutics in a research report on Tuesday, October 31st. Two equities research analysts have rated the stock with a sell rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $33.40.

Shares of Stemline Therapeutics (NASDAQ STML) opened at $15.55 on Monday. Stemline Therapeutics has a 12-month low of $5.50 and a 12-month high of $15.60.

ILLEGAL ACTIVITY NOTICE: “Stemline Therapeutics (STML) Given Daily News Sentiment Score of 0.17” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Insider Buying and Selling by Quarter for Stemline Therapeutics (NASDAQ:STML)

What are top analysts saying about Stemline Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Stemline Therapeutics Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit